Microbial therapeutics: New opportunities for drug delivery.

Advanced Search

Miguel Jimenez, Robert Langer, Giovanni Traverso

Author Information

Miguel Jimenez: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA. ORCID
Robert Langer: David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA rlanger@mit.edu.
Giovanni Traverso: Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA ctraverso@bwh.harvard.edu. ORCID

PMID: 31028093 DOI: 10.1084/jem.20190609

With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.

Microb Cell Fact. 2006 Jun 23;5:23 [PMID: 16796731]
Nat Rev Gastroenterol Hepatol. 2010 Sep;7(9):503-14 [PMID: 20664519]
J Ind Microbiol Biotechnol. 2012 Mar;39(3):383-99 [PMID: 22252444]
Sci Transl Med. 2012 Jun 6;4(137):137rv5 [PMID: 22674555]
N Engl J Med. 2013 Jan 31;368(5):474-5 [PMID: 23323865]
Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):44-54 [PMID: 27158095]
Nat Chem Biol. 2018 Jun;14(6):530-537 [PMID: 29769737]
Sci Transl Med. 2019 Jan 16;11(475):null [PMID: 30651324]
Nat Biotechnol. 1997 Dec;15(13):1351-7 [PMID: 9415886]

Bifidobacterium

Clostridium

Clostridium Infections

Drug Compounding

Drug Delivery Systems

Drug Dosage Calculations

Escherichia coli

Fecal Microbiota Transplantation

Gastrointestinal Microbiome

Humans

Vaccines, Live, Unattenuated

Journal Article Research Support, Non-U.S. Gov't

OpenLB
Open Library of Bioscience